Jeremy Bender Sells 9,154 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 9,154 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $17.85, for a total value of $163,398.90. Following the sale, the chief executive officer now directly owns 642,602 shares of the company’s stock, valued at approximately $11,470,445.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jeremy Bender also recently made the following trade(s):

• On Wednesday, May 1st, Jeremy Bender sold 70,051 shares of Day One Biopharmaceuticals stock. The stock was sold at an average price of $17.88, for a total value of $1,252,511.88.
• On Friday, February 16th, Jeremy Bender sold 7,615 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $15.25, for a total transaction of $116,128.75.

Day One Biopharmaceuticals Trading Down 2.3 %

Day One Biopharmaceuticals stock opened at $17.17 on Monday. The firm has a market capitalization of $1.50 billion, a P/E ratio of -7.21 and a beta of -1.44. Day One Biopharmaceuticals, Inc. has a twelve month low of $9.67 and a twelve month high of $18.07. The stock’s fifty day simple moving average is $15.45 and its 200-day simple moving average is $14.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). Sell-side analysts predict that Day One Biopharmaceuticals, Inc. will post -2.67 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on DAWN shares. The Goldman Sachs Group reduced their price target on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. Wedbush restated an “outperform” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, April 24th. Piper Sandler restated an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. Needham & Company LLC boosted their price objective on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Finally, HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, April 24th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $39.33.

Institutional Trading of Day One Biopharmaceuticals

Large investors have recently made changes to their positions in the company. SG Americas Securities LLC grew its holdings in Day One Biopharmaceuticals by 58.7% during the 3rd quarter. SG Americas Securities LLC now owns 36,980 shares of the company’s stock worth $454,000 after acquiring an additional 13,683 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Day One Biopharmaceuticals by 22.4% during the third quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock worth $2,703,000 after purchasing an additional 40,387 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Day One Biopharmaceuticals by 24.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 43,567 shares of the company’s stock valued at $535,000 after buying an additional 8,522 shares during the last quarter. TD Asset Management Inc raised its stake in Day One Biopharmaceuticals by 100.0% in the third quarter. TD Asset Management Inc now owns 55,196 shares of the company’s stock valued at $677,000 after buying an additional 27,598 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its stake in Day One Biopharmaceuticals by 89.5% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 53,803 shares of the company’s stock valued at $660,000 after buying an additional 25,414 shares in the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.